Literature DB >> 21569703

[Application of FICTION technique to the detection of genetic aberrations in multiple myeloma].

Di Wang1, Liang Huang, Heng Zhang, Zhe Geng, Zhen Shang, Jian-feng Zhou, Chun-rui Li.   

Abstract

OBJECTIVE: To investigate the diagnostic value of FICTION (Fluorescence Immunophenotyping and Interphase Cytogenetics as a Tool for the Investigation of Neoplasms) technique, combining immunofluorescence and fluorescence in situ hybridization (FISH), to detect genetic aberrations in multiple myeloma (MM).
METHODS: Bone marrow samples were collected from 18 MM and 2 plasma cell leukemia (PCL) patients. Probes targeting IgH and MMSET were prepared using a Nick Translation Kit from Bacterial artificial chromosome (BAC) clones. The immunophenotyping was achieved via the CD138 tyramide signal amplification (TSA)-mediated immunofluorescence, followed by FISH with the prepared probes \[t(4;14), t(11;14), t(14;16)\] and the commercial deletion probes (13q and p53) to detect common genetic aberrations in MM.
RESULTS: All the 20 samples were assayed with the probes mentioned above, and revealed 4 cases with t(4;14), 6 with t(11;14), 1 with t(14;16), 3 with p53 deletion; and 8 with 13q deletion. The remaining 4 cases had none of the 5 aberrations.
CONCLUSION: FICTION technique facilitates the detection of genetic abnormalities of MM in situ; enhances both efficiency and sensitivity of positive detection, thus, could be used as the screening test of molecular diagnosis of MM to guide coming-up risk-adapted therapy and evaluate prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21569703

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  1 in total

1.  Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma.

Authors:  Jihye Ha; Hyunsoo Cho; Taek Gyu Lee; Saeam Shin; Haerim Chung; Ji Eun Jang; Soo-Jeong Kim; June-Won Cheong; Seung-Tae Lee; Jin Seok Kim; Jong Rak Choi
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.